Alternative splicing of c-fos pre-mRNA: contribution of the rates of synthesis and degradation to the copy number of each transcript isoform and detection of a truncated c-Fos immunoreactive species
© Jurado et al; licensee BioMed Central Ltd. 2007
Received: 11 December 2006
Accepted: 21 September 2007
Published: 21 September 2007
Alternative splicing is a widespread mechanism of gene expression regulation. Previous analyses based on conventional RT-PCR reported the presence of an unspliced c-fos transcript in several mammalian systems. Compared to the well-defined knowledge on the alternative splicing of fosB, the physiological relevance of the unspliced c-fos transcript in regulating c-fos expression remains largely unknown. This work aimed to investigate the functional significance of the alternative splicing c-fos pre-mRNA.
A set of primers was designed to demonstrate that, whereas introns 1 and 2 are regularly spliced from primary c-fos transcript, intron 3 remains unspliced in part of total transcript molecules. Here, the two species are referred to as c-fos-2 (+ intron 3) and spliced c-fos (- intron 3) transcripts. Then, we used a quantitatively rigorous approach based on real-time PCR to provide, for the first time, the actual steady-state copy numbers of the two c-fos transcripts. We tested how the mouse-organ context and mouse-gestational age, the synthesis and turnover rates of the investigated transcripts, and the serum stimulation of quiescent cells modulate their absolute-expression profiles. Intron 3 generates an in-frame premature termination codon that predicts the synthesis of a truncated c-Fos protein. This prediction was evaluated by immunoaffinity chromatography purification of c-Fos proteins.
We demonstrate that: (i) The c-fos-2 transcript is ubiquitously synthesized either in vivo or in vitro, in amounts that are higher or similar to those of mRNAs coding for other Fos family members, like FosB, ΔFosB, Fra-1 or Fra-2. (ii) Intron 3 confers to c-fos-2 an outstanding destabilizing effect of about 6-fold. (iii) Major determinant of c-fos-2 steady-state levels in cultured cells is its remarkably high rate of synthesis. (iv) Rapid changes in the synthesis and/or degradation rates of both c-fos transcripts in serum-stimulated cells give rise to rapid and transient changes in their relative proportions. Taken as a whole, these findings suggest a co-ordinated fine-tune of the two c-fos transcript species, supporting the notion that the alternative processing of the precursor mRNA might be physiologically relevant. Moreover, we detected a c-Fos immunoreactive species corresponding in mobility to the predicted truncated variant.
Activator protein-1 (AP-1) is a dimeric transcription factor regulating major physiological processes such as cell proliferation, differentiation, neoplastic transformation, apoptosis, and response to stress . Main AP-1 components in mammals are members of the Fos and Jun protein families. The Fos family includes the products of the c-fos (the cellular counterpart of oncogene v-fos), fosB, fra-1 and fra-2 genes. Fos proteins associate with Jun, but also with other basic leucine-zipper (bZIP) proteins to create a variety of AP-1 complexes .
The expression of c-fos is subjected to a tight regulation at multiple levels. The c-fos gene undergoes rapid and transient transcriptional activation in response to a variety of extracellular stimuli . Both c-fos mRNA and protein turn over with short half-lives [4, 5]. Additionally, when the c-Fos protein is over-synthesized, the c-fos gene is transcriptionally repressed .
Alternative splicing is a widespread mechanism of gene expression regulation. The typical form of this regulation results from tissue- or temporal-specific splicing events that lead to the synthesis of either productive (protein-coding) or non-productive (no protein- coding) RNAs. Regarding transcription factors, alternative splicing preferentially adds or deletes domains that are important for their architectures and functions ( and references herein). The production of multiple isoforms is a common strategy for regulating the activity of genes within the Fos family (e.g. ). A particularly instructive example is the differential splicing of the fosB transcript, which generates two mRNAs that encode proteins with antagonistic activities. Briefly, alternative splicing removes codons 238–284 and causes a shift in the reading frame that places a stop codon following the bZIP region. The truncated protein (referred to as ΔFosB), missing the C-terminal 101 aa of FosB, functions as a trans-negative regulator of transcriptional activation and transformation, presumably by competing with the full-length Fos protein in the dimerization with Jun and binding to DNA steps [9–11].
Previous analyses [12, 13] based on RT of total RNA followed by conventional PCR have reported the presence of a transcript isoform (hereinafter referred to as c-fos-2) in several mammalian systems: (i) rat brain following kainic acid treatment, (ii) primary cortical culture of mouse brain treated with lipopolysaccharide, (iii) cartilage from newborn mouse, and (iv) mouse and human cultured stromal cells. Compared to the well-defined knowledge on the alternative splicing of fosB, the physiological relevance of c-fos-2 transcript in regulating c-fos expression has not been well addressed.
The work described herein aimed to gain further insights into the functional significance of the alternative splicing of c-fos. To this end, we first undertook a systematic and meticulous quantitation of the real copy numbers of c-fos transcript variants by means of a real-time PCR methodology [14–17]. We tested how the organ context, gestational age, synthesis and turnover rates, and serum stimulation of quiescent cells modulate the absolute expression profiles of the investigated c-fos transcripts. The translation of these transcripts predicts the synthesis of a truncated c-Fos protein, in addition to the canonical full-length counterpart. From cultured cells we partially purified a c-Fos immunoreactive species corresponding in mobility to the predicted truncated species.
Alternative splicing variants of c-fos messenger
Steady-state molecules of c-fos transcripts in animal tissues and cultured cells
Here we used a quantitatively rigorous approach based on RT and real-time PCR amplification [14–17] to provide novel information on the actual steady-state copy numbers of the two c-fos transcripts. Quantitations were carried out in adult mouse organs, whole mouse embryos at different developmental stages, and murine cultured cells.
The c-fos-2 variant was present in smaller amounts in all 8-tissue samples, where its presence accounted for different percentages of the total transcript molecules, ranging from more than 20% in lung and ovary to about 2% in testis. Regarding whole embryos, an over 7-fold overexpression in both c-fos transcripts occurred as early as E7 (gastrulating embryos). Thereafter, their amounts declined to approximately the average numbers of the steady-state copies measured in adult tissues. Therefore, the c-fos-2 species accounted for a constant 8–9% of the total transcript molecules throughout mouse embryonic development.
Absolute steady-state levels of transcripts encoding proteins of the Fos family in mouse lung
mean ± SEM
3.22 ± 0.23
0.56 ± 0.053
0.027 ± 0.003
1.20 ± 0.050
2.44 ± 0.11
Differential stability of the two c-fos transcripts
The steady-state abundance of any transcript depends on the balance between two opposing factors, its rate of formation and degradation. We show that though both c-fos transcripts are similarly abundant in cultured cells, the c-fos- 2 turned over about 6-fold faster than the spliced c-fos mRNA. Both findings can only be conciliated if, at the same time, the c-fos- 2 isoform is produced at a higher rate. Having determined the numbers of transcript copies and the transcript half-lives, we can estimate their synthesis rates. The result of such a calculation (Fig. 4B) suggests that the major determinant of c-fos- 2 transcript level in cultured cells is its high rate of synthesis, as compared to that of the spliced c-fos variant, and particularly to those of both fosB and of non proto-oncogenes mRNAs.
Transcript levels upon serum stimulation
Previous studies have shown that the stimulation of quiescent cells with 15% CS causes a rapid transient increase in c-fos mRNA . To gain more insight into the mechanisms that might be influencing the cellular level of the alternative c-fos-2 transcript, we decided to analyse whether its accumulation mode after serum induction was identical or not to that of the canonical spliced mRNA.
Rates of synthesis and degradation of c-fos and c-fos-2 transcripts upon serum stimulation
NIH 3T3 cells
serum (15 min)
serum (60 min)
Translation of c-fos-2 transcript
c-Fos proto-oncoprotein is a key cell regulator, whose improper expression is oncogenic, both in cultured cells and living organisms. To avoid the deleterious effects of deregulated expression, c-fos is subjected to numerous transcriptional and posttranscriptional controls . Differential pre-mRNA splicing is an important mode of regulating the activity of mammalian genes (e.g. ). Our interest in c-fos splicing stems from previous studies on fosB where a truncated spliced variant missing the C-terminus of FosB appears to be of great physiological relevance, e.g. in mediating long-term adaptive changes in the nervous system .
Murine c-fos gene comprises 4 exons and 3 introns spanning ~3.4 kb of chromosome 12. By means of specific primers, we first explored the presence of intron sequences in the transcript population derived from c-fos. We demonstrated that whereas introns 1 and 2 are regularly spliced from the precursor RNA, intron 3 remains unspliced in part of the total transcript molecules. Following this finding, we performed a robust and sensitive RT-PCR methodology for providing for the first time a comprehensive quantitation of the absolute expression levels of each transcript isoform: the canonical spliced c-fos and the alternative c-fos-2. Comparisons of expression levels across 8 mouse organs, 3 fetal stages and 2 cultured cell lines led to four observations: (i) The c-fos-2 transcript is ubiquitously synthesized either in vivo or in vitro situations. (ii) This isoform is present in amounts that are higher or similar to those of mRNAs coding for other Fos family members like FosB, ΔFosB, Fra-1 or Fra-2. (iii) The c-fos-2 variant is frequently processed in certain mouse tissues, like ovary and lung, and in confluent cell cultures, where both transcript isoforms are produced in about equal quantities. (iv) No obvious relationship exists between total amount of c-fos transcripts and the relative quantity of the c-fos-2 form. For instance, c-fos-2 accounted for about 9% of total transcript molecules in liver and about 6% in brain, though this last organ exceeds the hepatic steady-state amount by over 75-fold. On the whole, these findings support the notion that the c-fos-2 copy number might be controlled.
The number of copies of any transcript is determined by a delicate balance between opposing synthesis and degradation mechanisms. Here we show that the presence of intron 3 confers to the c-fos-2 transcript a destabilizing effect of about 6-fold, e.g. reducing the transcript half-life from 18 to 3 min in confluent NIH 3T3 cells (Fig. 4).
The canonical c-fos mRNA is targeted for decay by two functionally independent instability determinants. One of these determinants (designated mCRD) is located in the protein-coding region and the other (an AU-rich element) in the 3'-untranslated end of the c-fos mRNA . The mRNA decay mediated by mCRD represents a "suicide" mechanism in which translation of the mCRD-containing RNA results in the rapid degradation of the message . Here we show that the half-lives of the c-fos and c-fos-2 transcripts are affected differently by inhibition of the translation, since cycloheximide caused the stabilization of only the canonical c-fos mRNA (Fig. 5). This result suggests that the shorter half-life of the alternative c-fos-2 species is independent of translationally coupled mRNA turnover mechanisms, like the one directed by the mCRD determinant. Accordingly, the c-fos-2 transcript with the PTC lying in the last intron 3 (Fig. 8A) should be also immune to the so-called nonsense-mediated decay (NMD). It is noteworthy that this latter was anticipated given that one critical determinant of whether a mammalian transcript is subjected to NMD is the presence of a splicing-generated exon-exon junction >50–55 nt downstream the PTC (recently reviewed in  and ). In the absence of these two translationally coupled mRNA turnover mechanisms, an intriguing question remains to be answered: Why is the c-fos-2 transcript degraded at a faster rate than the canonical c-fos message?.
A recent paper by Moraes et al  indicates that the CUG-binding protein (CUG-BP) plays a role in c-fos mRNA decay. By means of an in vitro deadenylation assay, they showed that CUG-BP binding to c-fos mRNA stimulates the poly(A) shortening by the PARN deadenylase. Since deadenylation is a rate-limiting step in the turnover of most mRNAs, we hypothesized that the presence of intron 3 in the c-fos-2 transcript might accelerate its decay by the above-referred mechanism. We reasoned that in this case, the proportion between both c-fos transcript variants might change when using an anchored oligo(dT)primer (5'-T20VN-3'), rather than random primers, in the cDNA synthesis. This approach allowed us to track specifically the transcripts that retained poly(A)+ tails of a sufficient length to allow priming. We found [see Additional file 4] that the poly(A)+ population has practically the same copy numbers of c-fos and c-fos-2 transcripts as the overall RNA population. Moreover, the rate at which each transcript disappeared from the poly(A)+ population was similar to their overall decay rates [see Additional file 4]. These data seem to favour the idea that the two transcripts undergo deadenylation at the same rate, which seems to be in agreement with the synchronous deadenylation pattern seen for c-fos RNA both in vivo and in vitro [26, 27]. Further work should pursue the identification of new instability determinants within the c-fos-2 transcript variant.
Shur et al  have recently reported rapid changes in c-fos-2 and c-fos transcript levels in response of the osteoblastic cells to a challenge with dexamethasone (a pharmacological glucocorticoid hormone). Control of c-fos splicing through the interaction of the glucocorticoid receptor with the c-fos-2 transcript was the mechanism proposed to explain the observed changes. Here we too show that the proportion between both c-fos transcript variants changes rapidly and transiently upon the stimulation by serum of NIH 3T3 fibroblasts in quiescence. Our data indicate that differential rates of synthesis determine the large up-regulation of spliced c-fos relative to c-fos-2 level at the early stage of the serum response. However, destabilization of the newly synthesized c-fos message, possibly as it is being translated, contributes to completing the response and restoring the ~50% yield (percentage of total transcript molecules) quantitated in confluent cultures. This temporal sequence of events further supports the idea that the alternative processing of the primary c-fos transcript might be of physiological relevance, given that a relatively short extension of c-fos expression is sufficient for fibroblasts to manifest properties of cell transformation .
Translation of the c-fos-2 transcript predicts the synthesis of a truncated protein lacking 211 aa at the carboxyl-terminus. We partially purified by immunoaffinity chromatography a c-Fos protein (verified by Western blot) with an apparent molecular weight of 23-kDa as judged by SDS-polyacrylamide gel electrophoresis. This finding suggests that the truncated variant of c-Fos is expressed in NIH 3T3 cells. The truncation would occur after the conserved basic domain for DNA binding but prior to the adjacent leucine zipper for dimerization (Fig. 8). Therefore, the truncated c-Fos should be inactive for transformation and transactivation since the functional integrity of the bZIP motif is required for these activities . Moreover, the truncated c-Fos (unable to heterodimerize) should not exhibit antagonistic functional properties with the canonical longer counterpart, as in the case of ΔfosB [9–11]. On the other hand, however, the truncated c-Fos species might gain in stability as predicted by the loss of the main destabilizing activity residing at the C-terminal region [30, 31].
What might the biological significance of the above-referred truncated variant of c-Fos protein be? One could speculate with the idea that the truncated species is just the side effect of the c-fos-2 translation occurring or tolerated in the cells. Nonetheless, a more active role in regulating gene expression could also be envisaged, since the truncated c-Fos would retain the DNA binding domain (Fig. 8). Two pathways have been described for binding dimeric proteins to DNA. In the dimer pathway, proteins first form dimers and then go on to bind DNA. Along the monomer pathway, a monomer•DNA complex is formed first, followed by recruitment of the second monomer to form the final complex. A growing number of dimeric DNA-binding proteins are able to form complexes with DNA via a monomer pathway. In fact, the monomer pathway is considered the best option for a faster and more specific formation of the final complex ( and references herein). Although Fos and Jun monomer•DNA complexes are difficult to observe, particularly in gel retardation experiments (e.g. see ), recent stopped-flow fluorescence studies on the kinetics of Fos•Jun•DNA complex formation indicate that both protein monomers bind DNA sequentially and assemble their dimerization interface while interacting with DNA . These data allow us to speculate with the possibility  that even low levels of the truncated c-Fos variant might influence AP-1 mediated gene expression through the formation of non-productive monomer•DNA intermediates at specific DNA target sites. Additional experiments would be required to support such a notion.
Here we provide the first absolute (molecule number) quantitative analysis of alternative spliced transcript isoforms derived from the c-fos precursor RNA. We confirm that intron 3 remains in the transcript population derived from c-fos. We demonstrate that this transcript (here referred as c-fos-2) is ubiquitously synthesized, either in vivo (various mouse-tissues, gestational-ages) or in vitro (different murine cell lines), in amounts that are higher or similar to those of mRNAs coding for other Fos family members. Changes in the synthesis and/or degradation rates of both isoforms (the canonical spliced c-fos mRNA and the c-fos-2 variant) indicate a co-ordinated fine-tune of transcript molecules, supporting the notion that the alternative processing of the c-fos precursor RNA might be physiologically relevant. Moreover, translation of the c-fos-2 transcript predicts the synthesis of a truncated c-Fos protein. We detected a c-Fos immunoreactive species corresponding in mobility to the predicted truncated protein.
Cell culture and treatments
NIH 3T3 (ATCC: CRL-1658) and Hepa1-6 (ATCC: CRL-1830) cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% calf serum (CS) or foetal bovine serum, respectively. For mRNA decay quantitation, cells were seeded into 75 cm2 flask at a density of 3 × 106 cells/flask and cultivated for 48 h before the addition of 10 μg/ml actinomycin D (AmD). At different times thereafter, cells were scraped, washed once with phosphate-buffered saline, and immediately frozen in liquid nitrogen for total RNA purification. For serum stimulation, NIH 3T3 cells were made quiescent by 48 h incubation in DMEM with 0.5% CS. Cultures were then stimulated by re-feeding quiescent cells with 15% CS. Cells were incubated further and collected at different times as for AmD treatment. Data presented are means of at least two independent cell cultures.
Primers directed against different regions of the c-fos and fosB genes (Fig. 1A) were designed with the Oligo 6.1 software (Molecular Biology Insights), as detailed in . Primer positions (Fig. 1B) were chosen to detect intron sequences in the transcript population derived from c-fos. For comparison, primers for quantitation of the two well-defined forms of fosB transcript were also designed [9–11]. To obtain high specificity and performance, primers were required to have high Tm (≥82°C), optimal 3'-ΔG (≥ - 3 kcal/mol) value, and to be hairpin and duplex free. All primer pairs produced amplicons of the predicted size (Fig. 1C). All PCR products were further verified by nucleotide sequencing (ABI 377 DNA sequencer).
RNA preparations and reverse transcription
Total RNA was extracted by using Tri-Reagent™ (Sigma) according to the manufacturer's protocol. Contaminating genomic DNA was removed by DNase I (Ambion). RNA quality was checked electrophoretically and quantitation was made spectrophotometrically. Lack of DNA contamination was confirmed by PCR amplification of RNA samples without previous cDNA synthesis. The standard RNA was synthesized in vitro from a laboratory-engineered DNA fragment containing a T7 polymerase-binding site, by means of a commercial RNA transcription kit (Stratagene). cDNA was generated from 2 μg of total RNA from each sample, using the M-MLV reverse transcriptase (Life Technologies) and random hexamers (Invitrogen).
Real-time PCR reactions were performed in quadruplicate by using 50 ng of cDNA template, 0.3 μM of each primer (Fig. 1), 3 mM MgCl2, 250 μM of each dNTP, 0.75 units of Platinum Taq DNA polymerase, and 1:100000 SYBR Green I dye (Roche) in a volume of 25 μl. Reactions were analyzed on an iCycler iQ Real-Time PCR System (BioRad). Cycling conditions were as follows: 2 min at 95°C for the Platinum Taq activation and 40 cycles for the melting (15 s, 95°C) and annealing/extension (30 s, 70°C) steps. Replicate PCR reactions generated highly reproducible results with SEM <10% of the mean (<1% for threshold cycle) [see Additional file 5]. No primer-dimers were detected. Primers used for absolute quantitation of c-fos and fosB transcripts showed optimal (~100%) PCR efficiencies in the range of 20 to 2 × 105 pg of total RNA input with high linearity (r > 0.99) [see Additional file 6]. An absolute calibration curve was constructed with an external standard in the range of 102 to 109 RNA molecules [see Additional file 5]. The number of transcript molecules was calculated from the linear regression of the standard curve, as described previously  and exemplified in Additional file 5. The amount of c-fos mRNA molecules lacking intron 3 was estimated by subtracting the molecules with intron 3 (determined with E3U-I3L) from the total molecule number (determined with E3U-E4L). Similarly, the amount of mRNA molecules coding for ΔFosB was estimated by subtracting the molecules for the full-length FosB (determined with I4U-I4L) from the total molecule number (determined with E4U-E5L) (Fig. 1).
Immunoaffinity purification of c-Fos proteins
Rabbit polyclonal Ab (Calbiochem, PC05) against the N-terminal region (aa 4–17) shared by the full-length and the putative truncated c-Fos protein were coupled to cyanogen bromide (CNBr)-activated agarose (Sigma C9142) following the manufacturer's recommendations. NIH 3T3 cells were cultured as described above. The accumulation of c-Fos proteins was promoted by 30 min serum stimulation. The cells were harvested and then lysed in 150 μl of buffer A (50 mM Tris-HCl pH7.4, 150 mM NaCl, 0.03% Tween 20, 0.4 mM Na3VO4, 0.4 mM EDTA, 10 mM NaF, 10 mM sodium pyrophosphate, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride), by using a polypropylene pestle for microcentrifuge tubes mounted in a cordless motor and 4 cycles of freezing in liquid nitrogen and thawing at room temperature. The cell lysate was centrifuged at 16000 × g for 10 min at 4°C. The resulting supernatant (crude extract) was applied to the immunoaffinity column, which was then washed extensively with buffer A. The bound proteins were eluted with two volumes of 100 mM glycine-HCl (pH 2.8). The eluate from the immunoaffinity column was neutralized with NaOH for Western blot analysis as described below.
Proteins were separated on 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel and transferred onto Hybond-P PVDF membrane (Amersham Biosciences) by electroblotting. Membranes were blocked with 2% non-fat milk powder in TTBS (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.03% Tween-20) for 4–5 h at room temperature and then incubated overnight with 1:250 of primary Ab (Anti-c-Fos, Calbiochem PC05) in blocking buffer at 4°C. After washing the blots with blocking buffer, the membranes were incubated with 1:4000 of a secondary anti-rabbit IgG Ab (Sigma, A9169) to which horseradish peroxidase had been covalently coupled. Blots were developed using the ECL-Plus kit (Amersham Biosciences) following the manufacturer's instructions. The membranes were stripped by washing 30 min in stripping buffer (0.2 M glycine pH2.5, 0.1% SDS) at room temperature and reprobed with 1:2000 of anti-GAPDH Ab (Santa Cruz Biotechnology, sc-25778) for control loading.
polymerase chain reaction
Dulbecco's modified Eagle medium
premature termination codon
The work was supported by the Spanish Ministerio de Educación y Ciencia (Grant BFU2005-02896) and co-financed by FEDER funds. JJ and MJP-A were funded by the Spanish Ministerio de Ciencia y Tecnología (Ramón y Cajal Programme). CAF-A was recipient of a predoctoral fellowship from the Spanish Ministerio de Educación y Ciencia (Formación de Personal Investigador Programme).
- Hess J, Angel P, Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004,117(Pt 25):5965-5973. 10.1242/jcs.01589.View ArticlePubMed
- Milde-Langosch K: The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005,41(16):2449-2461. 10.1016/j.ejca.2005.08.008.View ArticlePubMed
- Greenberg ME, Greene LA, Ziff EB: Nerve growth factor and epidermal growth factor induce rapid transient changes in proto-oncogene transcription in PC12 cells. J Biol Chem 1985,260(26):14101-14110.PubMed
- Curran T, Miller AD, Zokas L, Verma IM: Viral and cellular fos proteins: a comparative analysis. Cell 1984,36(2):259-268. 10.1016/0092-8674(84)90219-8.View ArticlePubMed
- Rahmsdorf HJ, Schonthal A, Angel P, Litfin M, Ruther U, Herrlich P: Posttranscriptional regulation of c-fos mRNA expression. Nucleic Acids Res 1987,15(4):1643-1659. 10.1093/nar/15.4.1643.PubMed CentralView ArticlePubMed
- Cahill MA: c-Fos transrepression revisited. FEBS Lett 1997,400(1):9-10. 10.1016/S0014-5793(96)01349-X.View ArticlePubMed
- Taneri B, Snyder B, Novoradovsky A, Gaasterland T: Alternative splicing of mouse transcription factors affects their DNA-binding domain architecture and is tissue specific. Genome Biol 2004,5(10):R75. 10.1186/gb-2004-5-10-r75.PubMed CentralView ArticlePubMed
- Sherwood DR, Butler JA, Kramer JM, Sternberg PW: FOS-1 promotes basement-membrane removal during anchor-cell invasion in C. elegans. Cell 2005,121(6):951-962. 10.1016/j.cell.2005.03.031.View ArticlePubMed
- Nakabeppu Y, Nathans D: A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell 1991,64(4):751-759. 10.1016/0092-8674(91)90504-R.View ArticlePubMed
- Yen J, Wisdom RM, Tratner I, Verma IM: An alternative spliced form of FosB is a negative regulator of transcriptional activation and transformation by Fos proteins. Proc Natl Acad Sci U S A 1991,88(12):5077-5081. 10.1073/pnas.88.12.5077.PubMed CentralView ArticlePubMed
- Mumberg D, Lucibello FC, Schuermann M, Muller R: Alternative splicing of fosB transcripts results in differentially expressed mRNAs encoding functionally antagonistic proteins. Genes Dev 1991,5(7):1212-1223. 10.1101/gad.5.7.1212.View ArticlePubMed
- Feng Z, Kong LY, Qi Q, Ho SL, Tiao N, Bing G, Han YF: Induction of unspliced c-fos messenger RNA in rodent brain by kainic acid and lipopolysaccharide. Neurosci Lett 2001,305(1):17-20. 10.1016/S0304-3940(01)01793-1.View ArticlePubMed
- Shur I, Socher R, Benayahu D: Dexamethasone regulation of cFos mRNA in osteoprogenitors. J Cell Physiol 2005,202(1):240-245. 10.1002/jcp.20113.View ArticlePubMed
- Jiménez A, Prieto-Álamo MJ, Fuentes-Almagro CA, Jurado J, Gustafsson JA, Pueyo C, Miranda-Vizuete A: Absolute mRNA levels and transcriptional regulation of the mouse testis-specific thioredoxins. Biochem Biophys Res Commun 2005,330(1):65-74. 10.1016/j.bbrc.2005.02.128.View ArticlePubMed
- Jurado J, Prieto-Alamo MJ, Madrid-Risquez J, Pueyo C: Absolute gene expression patterns of thioredoxin and glutaredoxin redox systems in mouse. J Biol Chem 2003,278(46):45546-45554. 10.1074/jbc.M307866200.View ArticlePubMed
- Prieto-Álamo MJ, Cabrera-Luque JM, Pueyo C: Absolute quantitation of normal and ROS-induced patterns of gene expression: an in vivo real-time PCR study in mice. Gene Expr 2003,11(1):23-34.View ArticlePubMed
- Ruiz-Laguna J, Abril N, García-Barrera T, Gómez-Ariza JL, Lopez-Barea J, Pueyo C: Absolute transcript expression signatures of Cyp and Gst genes in Mus spretus to detect environmental contamination. Environ Sci Technol 2006,40(11):3646-3652. 10.1021/es060056e.View ArticlePubMed
- Monje-Casas F, Michan C, Pueyo C: Absolute transcript levels of thioredoxin- and glutathione-dependent redox systems in Saccharomyces cerevisiae: response to stress and modulation with growth. Biochem J 2004,383(Pt 1):139-147.PubMed CentralView ArticlePubMed
- Greenberg ME, Hermanowski AL, Ziff EB: Effect of protein synthesis inhibitors on growth factor activation of c-fos, c-myc, and actin gene transcription. Mol Cell Biol 1986,6(4):1050-1057.PubMed CentralView ArticlePubMed
- Coronella-Wood J, Terrand J, Sun H, Chen QM: c-Fos phosphorylation induced by H2O2 prevents proteasomal degradation of c-Fos in cardiomyocytes. J Biol Chem 2004,279(32):33567-33574. 10.1074/jbc.M404013200.View ArticlePubMed
- McClung CA, Ulery PG, Perrotti LI, Zachariou V, Berton O, Nestler EJ: ΔFosB: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res 2004,132(2):146-154. 10.1016/j.molbrainres.2004.05.014.View ArticlePubMed
- Shyu AB, Greenberg ME, Belasco JG: The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways. Genes Dev 1989,3(1):60-72. 10.1101/gad.3.1.60.View ArticlePubMed
- Grosset C, Chen CY, Xu N, Sonenberg N, Jacquemin-Sablon H, Shyu AB: A mechanism for translationally coupled mRNA turnover: Interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex. Cell 2000,103(1):29-40. 10.1016/S0092-8674(00)00102-1.View ArticlePubMed
- Wilkinson MF: A new function for nonsense-mediated mRNA-decay factors. Trends Genet 2005,21(3):143-148. 10.1016/j.tig.2005.01.007.View ArticlePubMed
- Lejeune F, Maquat LE: Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. Curr Opin Cell Biol 2005,17(3):309-315. 10.1016/j.ceb.2005.03.002.View ArticlePubMed
- Moraes KC, Wilusz CJ, Wilusz J: CUG-BP binds to RNA substrates and recruits PARN deadenylase. Rna 2006,12(6):1084-1091. 10.1261/rna.59606.PubMed CentralView ArticlePubMed
- Xu N, Chen CY, Shyu AB: Modulation of the fate of cytoplasmic mRNA by AU-rich elements: key sequence features controlling mRNA deadenylation and decay. Mol Cell Biol 1997,17(8):4611-4621.PubMed CentralView ArticlePubMed
- Miao GG, Curran T: Cell transformation by c-fos requires an extended period of expression and is independent of the cell cycle. Mol Cell Biol 1994,14(6):4295-4310.PubMed CentralView ArticlePubMed
- Schuermann M, Neuberg M, Hunter JB, Jenuwein T, Ryseck RP, Bravo R, Muller R: The leucine repeat motif in Fos protein mediates complex formation with Jun/AP-1 and is required for transformation. Cell 1989,56(3):507-516. 10.1016/0092-8674(89)90253-5.View ArticlePubMed
- Ferrara P, Andermarcher E, Bossis G, Acquaviva C, Brockly F, Jariel-Encontre I, Piechaczyk M: The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene 2003,22(10):1461-1474. 10.1038/sj.onc.1206266.View ArticlePubMed
- Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J: Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 2002,4(8):556-564.PubMed
- Kohler JJ, Schepartz A: Kinetic studies of Fos•Jun•DNA complex formation: DNA binding prior to dimerization. Biochemistry 2001,40(1):130-142. 10.1021/bi001881p.View ArticlePubMed
- Nakabeppu Y, Ryder K, Nathans D: DNA binding activities of three murine Jun proteins: stimulation by Fos. Cell 1988,55(5):907-915. 10.1016/0092-8674(88)90146-8.View ArticlePubMed
- Zondlo NJ, Schepartz A: Highly specific DNA recognition by a designed miniature protein. J Am Chem Soc 1999, 121: 6938-6939. 10.1021/ja990968z.View Article
- Pueyo C, Jurado J, Prieto-Alamo MJ, Monje-Casas F, Lopez-Barea J: Multiplex reverse transcription-polymerase chain reaction for determining transcriptional regulation of thioredoxin and glutaredoxin pathways. Methods Enzymol 2002, 347: 441-451.View ArticlePubMed
- Michán C, Monje-Casas F, Pueyo C: Transcript copy number of genes for DNA repair and translesion synthesis in yeast: contribution of transcription rate and mRNA stability to the steady-state level of each mRNA along with growth in glucose-fermentative medium. DNA Repair (Amst) 2005,4(4):469-478. 10.1016/j.dnarep.2004.12.001.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.